Proceedings of MATSUS Spring 2025 Conference (MATSUSSpring25)
DOI: https://doi.org/10.29363/nanoge.matsusspring.2025.440
Publication date: 16th December 2024
Overcoming biological barriers is essential for nanomedicines to reach their intended targets, requiring the exploration of "smarter" delivery nanosystems that can discern when and where to release specific compounds, thereby avoiding off-target effects. However, translating these concepts into clinical practice demands a deeper understanding of how synthetic nanomaterials interact with the complex biological environment.
Inspired by the natural interactions of cells, viruses, and exosomes within the body, biomimetic nanocarriers replicate the structure and functionality of cellular membranes. These carriers, designed using cellular components such as those from cancer cells, platelets, and macrophages, exhibit enhanced pharmacokinetics and tissue-specific targeting capabilities (Adv. Biosys, 2020, 4 (3), 1900260; J. Nanobiotechnol. 2022, 20, 538; J .Nanobiotechnol., 2024, 22 (1), 10).). Such nanocarriers can be programmed for a variety of specialized functions, including immune evasion, homotypic targeting, and direct cytosolic delivery via membrane fusion, bypassing traditional endo-lysosomal pathways. (J. Colloid Interface Sci. 2023, 648, 488-496; J. Colloid Interface Sci, 2024). The combination of engineered biomimetic coatings with nanosized metal-organic frameworks (nanoMOFs) represents a novel approach that integrates the homotypic targeting and fusogenic capabilities of cell-derived membranes with the high payload capacity of MOFs. This innovative system demonstrates efficient cellular internalization of therapeutic agents, reduced toxicity, and enhanced cytotoxic effects in both 2D cultures and 3D spheroid models. These findings highlight the system’s potential for precise drug delivery in cancer therapy and suggest opportunities to adapt this approach for various tumor types and therapeutic agents, advancing the field of precision nanomedicine.